Background: Gastroenteropancreatic neuroendocrine neoplasm (GEP–NEN) is a rare tumor, but with increasing global prevalence. However, data on epidemiology and survival in Latin America are sparse.

Objective: To describe clinical characteristics and survival in GEP–NEN treated at the Instituto Nacional de Cancerología in Bogotá, Colombia.

Methods: This retrospective observational study included patients diagnosed with GEP–NEN between January 1, 2008 and January 1, 2020. Clinical and pathological data were extracted from medical records. Survival analysis was conducted using Kaplan–Meier estimators and Cox proportional hazards models.

Results: A total of 204 patients were included. Median age was 55 years (range: 19–83); 61.3% were women. Most tumors (95.6%) were well-differentiated gastroenteropancreatic neuroendocrine tumors (NETs), and 55.9% of patients presented with stage IV disease. The most common primary tumor sites were the pancreas (25.5%) and the small intestine (23.5%). Median interval from symptom onset to diagnosis was 12 months, with 25% of patients requiring ≥2 years for diagnosis. Median follow-up was 105 months (95% CI: 87.6–115.2). Median overall survival was not reached. Poorer survival was significantly associated with higher tumor grade ( p < 0.001), age > 65 years ( p = 0.035), and metastatic disease at diagnosis ( p < 0.001). In contrast, surgical treatment was significantly associated with better overall survival ( p = 0.006).

Conclusions: This study provides real-world evidence on outcomes in GEP–NEN in Latin America. Tumor grade, age, surgical treatment and metastasis at diagnosis were identified as key prognostic factors, highlighting the importance of early diagnosis and timely intervention.